Categories
Archives
Receive Email Updates

-


-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me

Warren D. Woessner
Pages
Archives
Category Archives: Patent Eligible Subject Matter
Why Myriad Should Drop Its Appeal
In the Kenny Rogers song, “The Gambler,” Rogers sings “You got to know when to hold ‘em, know when to fold ‘em.” There is still time for Myriad to “fold ‘em” and drop its appeal of the district court decision … Continue reading
“In Leukemia Treatment, Glimpses of the Future” of Medicine and IP
A provocative article in the Sunday New York Times recounted how a young cancer researcher, who was diagnosed with acute lymphoblastic leukemia (ALL), and who responded but relapsed twice after receiving chemotherapy and bone marrow transplant, achieved a third remission … Continue reading
Posted in Patent Eligible Subject Matter
Tagged biotechnology law, FLT3, Mayo, Myriad, USPTO, Warren Woessner
Leave a comment
PTO Guidelines for Process Claims Involving Laws of Nature
On July 3rd, the PTO released 13 pages entitled “2012 Interim Procedure for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature.” They are intended as guidance for Examiners who encounter such claims, e.g., in Group 1600, in … Continue reading
Posted in Patent Eligible Subject Matter
Tagged Patent Law, Prometheus v. Mayo, Supreme Court, USPTO, Warren Woessner
1 Comment
Lilly Files Amicus Brief in Myriad Remand – With Friends Like This…
Following its reversal of the Fed. Cir.’s decision in Mayo v. Prometheus (“Mayo”), the Supreme Court GVR’d in response to AMP’s (read: ACLU’s) appeal of Myriad’s claims to isolated DNA sequences and to a method of screening potential anti-cancer drugs … Continue reading
